1188307-60-9

Basic information

• Product Name: (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(2-nitro-4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate
• Synonyms: (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(2-nitro-4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate
• CAS NO: 1188307-60-9
• Molecular Weight: 664.534
• Mol File: 1188307-60-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(2-nitro-4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(2-nitro-4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate(1188307-60-9)
• EPA Substance Registry System: (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(2-nitro-4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate(1188307-60-9)

Safety Data

• Hazardous Substances Data: 1188307-60-9(Hazardous Substances Data)

Upstream product

• 7693-46-1 4-Nitrophenyl chloroformate 
• 290298-12-3 (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(4-(hydroxymethyl)-2-nitrophenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 3068-32-4 1-bromo-1-deoxy-2,3,4,6-tetra-O-acetyl-a-D-galactopyranoside 
• 3011-34-5 4-hydroxy-3-nitrobenzaldehyde 
• 121358-46-1 (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(4-formyl-2-nitrophenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate 

Downstream Products

• 1188307-61-0 C₄₀H₄₆N₄O₂₀ 
• 1224946-46-6 N-methyl-N-[4-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-3-nitrobenzyl-oxycarbonyl]-2-aminoethanol 
• 1224946-42-2 N,N'-dimethyl-N-[4-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-3-nitrobenzyl-oxycarbonyl]-N'-(tert-butyloxycarbonyl)-ethylenediamine 

Relevant articles and documents

An Enzyme-Directed Imidazoquinoline for Cancer Immunotherapy

Herein we report the synthesis and activity of an enzyme-directed immunostimulant with immune cell activation mediated by β-galactosidase, either exogenously added, or on B16 melanoma cells. Covalent attachment of a β-galactopyranoside to an imidazoquinoline immunostimulant at a position critical for activity resulted in a pro-immunostimulant that could be selectively converted by β-galactosidase into an active immunostimulant. The pro-immunostimulant exhibited β-galactosidase-directed immune cell activation as measured by NF-κB transcription in RAW-Blue macrophages or cytokine production (TNF, IL-6, IL-12) in JAWSII monocytes. Conversion of the pro-immunostimulant into an active immunostimulant was also found to occur using β-galactosidase-enriched B16 melanoma cells. In co-culture experiments with either immune cell line, β-galactosidase-enriched B16 cells effected activation of bystander immune cells.

ENZYME-DIRECTED IMMUNOSTIMULANT AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATION(S)

The disclosed invention relates to the novel composition of matter that allows for the controlled release of highly active compounds to be delivered to a desired site. This novel composition utilizes the immune system to allow for the controlled release of desired compounds. The present invention can utilize a plurality of highly active compounds, with one embodiment being the use of chemotherapeutics for the treatment of cancer.

Rotaxane-based propeptides: protection and enzymatic release of a bioactive pentapeptide

-